Previous studies have reported that, in addition to PD-L1 and the tumor microenvironment, systemic inflammatory factors20, 21 and metabolic indicators22 can also predict the efficacy of immunotherapy in patients with driver gene-negative lung cancer. This evidence concerns the gene CD274 and neoplasm.